Intra-Cellular Therapies, Inc.
ITCI
Classificação em ações
#1692
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Preço da ação
$131.87
Última sincronização: 2025-04-02
Valor de mercado
$12.68B
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Intra-Cellular Therapies, Inc. (ITCI)
Categoria
Healthcare
EPS de Intra-Cellular Therapies, Inc. (ITCI)
EPS em December 2024 TTM: $-0.01
De acordo com os últimos relatórios financeiros e o preço das ações da Intra-Cellular Therapies, Inc., o EPS atual da empresa (TTM) é $-0.01. No final de 2023, a empresa teve um EPS de $-1.46, uma diminuição em relação a ao EPS de 2022, que foi de $-2.72.
Histórico de EPS da Intra-Cellular Therapies, Inc. de 2013 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-0.01 | -98.61% |
| 2024 | $-0.72 | -50.68% |
| 2023 | $-1.46 | -46.32% |
| 2022 | $-2.72 | -22.29% |
| 2021 | $-3.50 | 8.36% |
| 2020 | $-3.23 | 20.52% |
| 2019 | $-2.68 | -5.63% |
| 2018 | $-2.84 | 33.96% |
| 2017 | $-2.12 | -21.19% |
| 2016 | $-2.69 | -7.56% |
| 2015 | $-2.91 | 171.96% |
| 2014 | $-1.07 | -31.41% |
| 2013 | $-1.56 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -5,663.00% |
IN
|
